NAMSW
MaterialsNewAmsterdam Pharma Company NV - Warrants (15/11/2027)
Live · NASDAQ · May 9, Close
What's Moving NAMSW Today?
No stock-specific AI insight has been generated for NAMSW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$21.23
Fundamentals
Trading
NAMSW News
20 articles- Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?Yahoo Finance·May 8, 2026
- NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded TrendsMarketbeat·May 8, 2026
- NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsYahoo Finance·May 7, 2026
- A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C ResultsYahoo Finance·Apr 9, 2026
- NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan DruckenmillerYahoo Finance·Apr 8, 2026
- NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 2, 2026
- Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4Yahoo Finance·Apr 2, 2026
- Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS)Yahoo Finance·Mar 29, 2026
- NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific SessionYahoo Finance·Mar 23, 2026
- This Biotech Was Quietly Bought Before a $58 Per Share TakeoutMotley Fool·Mar 21, 2026
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MarchYahoo Finance·Feb 25, 2026
- The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share OfferingYahoo Finance·Feb 23, 2026
- NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Feb 18, 2026
- NewAmsterdam Pharma (NAMS) Revenue Forecast to Grow 59.1% Annually, Defying Persistent Losses and Valuation ConcernsYahoo Finance·Nov 6, 2025
- NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Nov 5, 2025
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial ResultsYahoo Finance·Nov 5, 2025
- NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in NovemberYahoo Finance·Oct 30, 2025
- NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·Oct 29, 2025
All 20 articles loaded
Price Data
52-Week Range
$21.23
Fundamentals
Trading
About NewAmsterdam Pharma Company NV - Warrants (15/11/2027)
NewAmsterdam Pharma Company N.V. is an innovative clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapeutics for cardiometabolic diseases, with a primary focus on dyslipidemia—a key contributor to cardiovascular risk. The company employs a rigorous scientific methodology alongside a robust R&D framework, positioning itself strategically for potential regulatory approval of its unique drug candidates. By addressing substantial unmet medical needs within this critical therapeutic area, NewAmsterdam seeks to significantly enhance patient outcomes while driving long-term value for shareholders, making it a compelling investment opportunity in the biopharmaceutical sector.